Skip to main content
. 2022 Sep 29;32:37. doi: 10.1038/s41533-022-00295-7

Table 2.

Asthma characteristics of the SABINA III PCP cohort according to investigator-classified asthma severity.

Asthma characteristics Primary care (n = 1440)
Investigator-classified mild asthmaa (n = 743) Investigator-classified moderate-to-severe asthmaa (n = 695) All (n = 1440)
Asthma duration, years
 Mean (SD) 17.9 (14.78) 16.5 (13.91) 17.2 (14.37)
 Median (min–max) 13.0 (1.0–73.0) 13.0 (1.0–70.0) 13.0 (1.0–73.0)
Number of severe asthma exacerbations 12 months before the study visit
 Mean (SD) 1.1 (2.99) 0.9 (1.60) 1.0 (2.42)
Number of severe asthma exacerbations 12 months before the study visit
 0 453 (61.0) 428 (61.6) 882 (61.3)
 1 129 (17.4) 130 (18.7) 259 (18.0)
 2 59 (7.9) 62 (8.9) 122 (8.5)
 3 47 (6.3) 32 (4.6) 79 (5.5)
 >3 55 (7.4) 43 (6.2) 98 (6.8)
 Total 743 (100.0) 695 (100.0) 1440 (100.0)
GINA classification
 Step 1 316 (42.5) 0 (0.0) 316 (21.9)
 Step 2 427 (57.5) 0 (0.0) 427 (29.7)
 Step 3 0 (0.0) 371 (53.4) 371 (25.8)
 Step 4 0 (0.0) 261 (37.6) 261 (18.1)
 Step 5 0 (0.0) 63 (9.1) 63 (4.4)
 Missing data 0 (0.0) 0 (0.0) 2 (0.1)
 Total 743 (100.0) 695 (100.0) 1440 (100.0)
Level of asthma control
 Well controlled 318 (42.8) 282 (40.6) 601 (41.7)
 Partly controlled 244 (32.8) 258 (37.1) 503 (34.9)
 Uncontrolled 181 (24.4) 155 (22.3) 336 (23.3)
 Total 743 (100.0) 695 (100.0) 1440 (100.0)
Number of comorbidities
 0 328 (44.1) 264 (38) 593 (41.2)
 1–2 319 (42.9) 276 (39.7) 596 (41.4)
 3–4 89 (12) 126 (18.1) 215 (14.9)
 ≥5 7 (0.9) 29 (4.2) 36 (2.5)

Data are presented as n (%) unless otherwise specified. aInvestigator-classified asthma severity was guided by GINA 2017 treatment steps. Investigators were guided by GINA 2017 treatment steps, either in the study protocol or via a pop-up window in the eCRF.

eCRF electronic case report form, GINA Global Initiative for Asthma, max maximum, min minimum, PCP primary care physician, SABINA SABA use IN Asthma, SD standard deviation.